US FDA misses financial conflicts among clinical trial physicians, says government report
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration does not do enough to guard against financial conflicts of interest among physicians who carry out clinical trials of pharmaceuticals and devices that have yet to receive marketing authorisation, a government report has found1.
You may also be interested in...
New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Merck Sharp & Dohme's Ebola vaccine, Ervebo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The Stakes Are High So Get It Right
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. Consultant Kate Dion highlights to In Vivo helpful tips for companies facing this daunting situation.
Vertex Inks Another Orkambi Reimbursement Deal After France Says Yes
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: